Literature DB >> 23377666

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy.

Vincent G Brichard, Jamila Louahed, Timothy M Clay.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23377666     DOI: 10.1097/CJI.0b013e3182829747

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


× No keyword cloud information.
  4 in total

Review 1.  Criteria to make animal studies more relevant to treating human cancer.

Authors:  Steven P Wolf; Frank T Wen; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2021-10-04       Impact factor: 7.486

Review 2.  Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.

Authors:  Leidy D Caraballo Galva; Lun Cai; Yanxia Shao; Yukai He
Journal:  J Genet Genomics       Date:  2020-01-28       Impact factor: 4.275

3.  MAGE-A Antigens and Cancer Immunotherapy.

Authors:  Paul Zajac; Elke Schultz-Thater; Luigi Tornillo; Charlotte Sadowski; Emanuele Trella; Chantal Mengus; Giandomenica Iezzi; Giulio C Spagnoli
Journal:  Front Med (Lausanne)       Date:  2017-03-08

4.  Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells.

Authors:  Lun Cai; Leidy D Caraballo Galva; Yibing Peng; Xiaobing Luo; Wei Zhu; Yihong Yao; Yun Ji; Yukai He
Journal:  Front Immunol       Date:  2020-04-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.